Indian firm Meril Life Sciences has signed an agreement with Japan’s leading cardiovascular medtech company, Japan Lifeline. This strategic alliance empowers Japan Lifeline to promote Meril’s next generation transcatheter heart valve, Myval Octacor, upon Pharmaceuticals and Medical Devices Agency (PMDA) approval in Japan.

Myval Octacor is a balloon-expandable transcatheter heart valve implant designed for Transcatheter Aortic Valve Replacement / Implantation (TAVR / TAVI) procedures. It features a wide range of sizes to fit a broader patient population as compared to legacy technology. It also has a unique octagonal cell structure that improves accuracy of placement.

More than 25,000 heart valves manufactured by Meril have been implanted across 75 countries over past 7 years with proven clinical safety, efficacy and are supported by 80+ scientific publications. Currently, Meril is the market leader in transcatheter heart valves in India and dedicates time and energy by supporting physician education as well as patient awareness regarding aortic valve disease amongst various cardiovascular diseases.